Episode
Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt
- Podcast
- Business Of Biotech
- Published
- Dec 1, 2025
- Duration seconds
- 3085
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product testing and development, using basket trials to evaluate chemotherapy combinations, and choosing pancreatic cancer as a lead program. He also talks about surviving an IPO during a brutal funding cycl...